Hyperactive behavior
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Finally, we offer testable predictions on the molecular drivers of PI3K oscillations, the timing of these oscillations with respect to division, and the role of altered Plk1 and FoxO activity in genome-level defects caused by hyperactive PI3K.
|
30875364 |
2019 |
Hyperactive behavior
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Tau aggregation occur by stimulation effects of Glycogen synthase kinase-3(GSK3β) and phosphatidylinositol 3-kinase (PI3K) which activates protein kinase B(Akt) and causes inhibition of phosphorylation(activation) of GSK3β, thus Akt activation can cause inhibition of tau aggregation (hyper-phosphorylation).
|
31203911 |
2019 |
Hyperactive behavior
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
PI3K/Akt/mTOR signaling pathway plays a vital role in regulating cell survival, differentiation, metabolism and migration, which is frequently hyperactive in a number of cancers, including esophageal squamous cell carcinoma (ESCC).
|
30119206 |
2018 |
Hyperactive behavior
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
These PIK3CA and PIK3R1 impactful mutations exhibit a mutually exclusive pattern, leading to oncogenesis and hyperactivity of PI3K pathway.
|
29636477 |
2018 |
Hyperactive behavior
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Compared with the situation of optimal salinity for oyster growth, hypo-salinity mainly regulated expression of genes involved in FoxO and oxytocin signaling, tight junction and several immune pathways, while hyper-salinity altered gene expression implicated in amino acid metabolism, AMPK and PI3K-AKt signaling pathways, demonstrating the complexity and plasticity of transcriptomic expression underpinning oyster eurysalinity.
|
30416453 |
2018 |
Hyperactive behavior
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The RAS-RAF-ERK and RAS-PI3K-AKT pathways are the major hyper-activated downstream pathways in RAS mutation, which promotes the unlimited lifecycle of cancer cells and their metastasis in humans.
|
30186180 |
2018 |
Hyperactive behavior
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Mechanistically, inhibition of mTOR activity with rapamycin resulted in a hyperactive PI3K-Akt pathway, whereas this activation inhibited the expression of CTGF in HPCs.
|
30135653 |
2018 |
Hyperactive behavior
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
PI3K Signaling in Tissue Hyper-Proliferation: From Overgrowth Syndromes to Kidney Cysts.
|
28353628 |
2017 |
Hyperactive behavior
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Hyper-activation of the MAPK and PI3K-AKT pathways is linked to tumour progression in triple-negative breast cancer (TNBC).
|
28576487 |
2017 |
Hyperactive behavior
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
We show that altered stoichiometry within the p85-p110 complex likely underlies the hyperactive PI3K-AKT-mTOR signaling in this instance.
|
26593112 |
2016 |
Hyperactive behavior
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
PI3K pathway was hyperactive (PIK3CA mutations and/or PTEN loss and/or AKT1 mutation) in 47% of BOLERO-1 and 41% of BOLERO-3 samples.
|
27091708 |
2016 |
Hyperactive behavior
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Therefore, the hyperactivity of PI3K/Akt pathway and elevated levels of p53R2 can give rise to highly invasive cancers.
|
25086499 |
2014 |
Hyperactive behavior
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The mutational profile often evidences a gain of function or hyperactivity of phosphoinositide 3-kinases (PI3Ks) in tumors.
|
24897931 |
2014 |
Hyperactive behavior
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
In breast cancers, pro-survival PI3K-Akt-mTOR-S6K1 [corrected] signaling pathway is often hyperactive due to overexpression of genes coding for growth factors or estrogen receptors, constitutive activation of PI3K or Akt and loss of PTEN, a negative regulator of the pathway.
|
23389114 |
2013 |
Hyperactive behavior
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
This suggests that, in CSCs of ERα-positive breast cancer, the PI3K pathway which is involved in endocrine resistance is hyperactive.
|
22771536 |
2012 |
Hyperactive behavior
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Our data suggest that adenovirus expressing a FKHRL1 triple mutant could be a useful vector for gene therapy of cancers resistant to chemotherapy and radiotherapy induced by hyperactivity of PI3K/Akt.
|
16861905 |
2006 |
Hyperactive behavior
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
We postulate that negative regulation of the PI 3-K/Akt pathway by PTEN may modulate the effects of the hyperactive epidermal growth factor receptor/mitogen-activated protein kinase pathway, contributing to the low proliferation and dysfunctional differentiation of laryngeal papillomas.
|
10728713 |
2000 |